Literature DB >> 14691454

Immunological and pathobiological roles of fibulin-1 in breast cancer.

Serenella M Pupa1, William S Argraves, Stefania Forti, Patrizia Casalini, Valeria Berno, Roberto Agresti, Piera Aiello, Annamaria Invernizzi, Paola Baldassari, Waleed O Twal, Roberta Mortarini, Andrea Anichini, Sylvie Ménard, Scott W Argraves.   

Abstract

Fibulin-1 (Fbln-1) is an immunogenic breast cancer-related glycoprotein identified by serological analysis of cDNA expression library (SEREX) strategy. Here, we show that dendritic cells from two breast cancer patients elicited a CD4(+)-mediated T-cell response to Fbln-1 presentation. In both patients, an antibody response to Fbln-1 was also found. By contrast, a Fbln-1-seronegative patient and a weakly seropositive patient demonstrated no such T-cell response. Analysis of human breast cancers for Fbln-1 RNA and protein expression revealed the presence of Fbln-1C and -1D variants. Fbln-1 was detected in the cytoplasm and at the cell surface of different human breast carcinoma cell lines. Immunohistochemical analysis of 528 archival primary breast carcinomas showed the expression of Fbln-1 in 35% of the cases. When the immunohistochemical findings were compared against pathobiological information associated with each specimen, an inverse relationship between Fbln-1 and cathepsin D expression was observed (P=0.04). Furthermore, even though long-term survival was similar between Fbln-1-positive and -negative cases, the survival of Fbln-1-positive cases improved when a lymphoid infiltrate was present at the tumour site. Taken together, our findings of an Fbln-1-specific immunity and the improved survival associated with Fbln-1 expression in the presence of lymphoid infiltration point to a role of Fbln-1 in tumour immunosurveillance.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 14691454     DOI: 10.1038/sj.onc.1207323

Source DB:  PubMed          Journal:  Oncogene        ISSN: 0950-9232            Impact factor:   9.867


  18 in total

1.  Expression of fibulin-1 predicted good prognosis in patients with colorectal cancer.

Authors:  Jing Zhu; Rui Chen; Lijuan Mo; Haimei Tang; Yeye Kuang; Weiqiang Fei; Chao He; Xiaotong Hu
Journal:  Am J Transl Res       Date:  2015-02-15       Impact factor: 4.060

2.  Experimental validation of 5 in-silico predicted glioma biomarkers.

Authors:  Rheal A Towner; Randy L Jensen; Brian Vaillant; Howard Colman; Debra Saunders; Cory B Giles; Jonathan D Wren
Journal:  Neuro Oncol       Date:  2013-10-24       Impact factor: 12.300

3.  Human breast fibroblasts inhibit growth of the MCF10AT xenograft model of proliferative breast disease.

Authors:  Andrea Sadlonova; Shibani Mukherjee; Damon B Bowe; Sandra R Gault; Nicole A Dumas; Brian A Van Tine; Natalya Frolova; Grier P Page; Danny R Welch; Lea Novak; Andra R Frost
Journal:  Am J Pathol       Date:  2007-03       Impact factor: 4.307

4.  Autoantibodies to tumor-associated antigens in breast carcinoma.

Authors:  Ettie Piura; Benjamin Piura
Journal:  J Oncol       Date:  2010-11-21       Impact factor: 4.375

5.  Fibulin-1 is increased in asthma--a novel mediator of airway remodeling?

Authors:  Justine Y Lau; Brian G Oliver; Melissa Baraket; Emma L Beckett; Nicole G Hansbro; Lyn M Moir; Steve D Wilton; Carolyn Williams; Paul S Foster; Philip M Hansbro; Judith L Black; Janette K Burgess
Journal:  PLoS One       Date:  2010-10-13       Impact factor: 3.240

6.  Fibulin-1 purification from human plasma using affinity chromatography on Factor H-Sepharose.

Authors:  Richard G DiScipio; Robert C Liddington; Ingrid U Schraufstatter
Journal:  Protein Expr Purif       Date:  2016-01-28       Impact factor: 1.650

7.  Identification of molecular distinctions between normal breast-associated fibroblasts and breast cancer-associated fibroblasts.

Authors:  Andrea Sadlonova; Damon B Bowe; Zdenek Novak; Shibani Mukherjee; Virginia E Duncan; Grier P Page; Andra R Frost
Journal:  Cancer Microenviron       Date:  2009-03-18

8.  Fibulin 1 is downregulated through promoter hypermethylation in gastric cancer.

Authors:  Y Y Cheng; H Jin; X Liu; J M T Siu; Y P Wong; E K O Ng; J Yu; W-K Leung; J J Y Sung; F K L Chan
Journal:  Br J Cancer       Date:  2008-11-04       Impact factor: 7.640

9.  Biological processes, properties and molecular wiring diagrams of candidate low-penetrance breast cancer susceptibility genes.

Authors:  Núria Bonifaci; Antoni Berenguer; Javier Díez; Oscar Reina; Ignacio Medina; Joaquín Dopazo; Víctor Moreno; Miguel Angel Pujana
Journal:  BMC Med Genomics       Date:  2008-12-18       Impact factor: 3.063

10.  Polycomb repressive complex 2 (PRC2) restricts hematopoietic stem cell activity.

Authors:  Ian J Majewski; Marnie E Blewitt; Carolyn A de Graaf; Edward J McManus; Melanie Bahlo; Adrienne A Hilton; Craig D Hyland; Gordon K Smyth; Jason E Corbin; Donald Metcalf; Warren S Alexander; Douglas J Hilton
Journal:  PLoS Biol       Date:  2008-04-15       Impact factor: 8.029

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.